# Does Montana Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Rules By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-07 Canonical page: https://glpwatchdog.org/research/montana-medicaid-glp1-coverage > Montana Medicaid will not pay for any drug used for weight loss. Its PA forms still approve Wegovy for heart disease or MASH, plus Zepbound for sleep apnea that CPAP has not controlled. Criteria, specialists, renewals and the 90-day appeal window. ## Key points - Montana's drug benefit names weight-loss drugs among the medicines it will not pay for. - Wegovy for heart risk needs a past heart attack, stroke or artery disease, a BMI over 27 and a cardiac specialist. - Wegovy for MASH needs a biopsy or FibroScan showing F2 to F3 scarring and a liver or GI specialist. - Zepbound for sleep apnea needs six months of PAP first, and is refused if CPAP brings the AHI under 15. - No route is open to people with type 2 diabetes, who use the diabetes GLP-1s; members have 90 days to request a hearing. No. As of November 2026, Montana Medicaid does not pay for Wegovy, Zepbound or any other drug used for weight loss; the state lists weight-loss drugs among the medicines it does not cover.[1] Its prior authorization forms do open three narrower routes for adults without type 2 diabetes: Wegovy for established heart disease or the liver disease MASH, and Zepbound for sleep apnea after six months on CPAP.[2][3] > **About this article.** This page reads the Montana Healthcare Programs prior authorization forms for Wegovy (dated August 2026) and Zepbound (dated November 2025), the preferred drug list of September 10, 2026, and the state’s pharmacy and hearing rules, as they stood on November 7, 2026. We could not read Montana’s own rules website, which we could not open, so the appeal rule comes from Cornell’s copy. To compare Montana with other states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker). ## Will Montana Medicaid pay for Wegovy or Zepbound to lose weight? It does not. The state’s plain-language guide to the drug benefit lists “drugs used for weight loss” next to fertility, cosmetic and hair-growth drugs as things the program will not pay for.[1] Neither Wegovy nor Zepbound appears on the September 2026 preferred drug list at all; they reach patients only through the stand-alone request forms described below.[4] This is legal under federal Medicaid law. Drugs used for weight loss are on a short list of drug types a state may leave out of its program.[7] Montana applies the exclusion to the drug’s purpose, not its name, which is why the same Wegovy pen can be refused for weight and approved for heart disease. Our explainer on [how Medicaid splits Ozempic from Wegovy](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal rule in more detail. ## Which GLP-1 uses does Montana Medicaid pay for? Four. Type 2 diabetes is the broadest; the other three match uses the FDA has added to the Wegovy and Zepbound labels beyond weight.[8][9] All three non-diabetes routes are run by Mountain Pacific, the organization that handles drug prior authorization for the state health department under contract.[5] *Montana Medicaid GLP-1 routes, from the Wegovy form (August 2026), Zepbound form (November 2025) and preferred drug list (September 10, 2026)* | Use | Drug | Main requirements | First approval | | --- | --- | --- | --- | | Weight loss alone | Wegovy, Zepbound | Not covered | None | | Type 2 diabetes | Ozempic, Trulicity, Victoza preferred; Mounjaro and others non-preferred | Non-preferred drugs need trials of 2 preferred drugs for 6 months each | Per diabetes edits | | Lowering heart attack and stroke risk | Wegovy | Age 18+; past heart attack, stroke or peripheral artery disease; BMI over 27; cardiac specialist; no type 2 diabetes | 12 months | | MASH with F2 to F3 fibrosis | Wegovy | Age 18+; FibroScan-type ultrasound or biopsy; GI or liver specialist; no type 2 diabetes | 12 months | | Moderate to severe sleep apnea | Zepbound | Age 18+; AHI 15+ within 12 months; BMI 30+; sleep specialist; 6 months of PAP that leaves AHI at 15+; no type 2 diabetes | 6 months | Every non-diabetes route carries the same line: the prescriber must attest that the patient has no type 2 diabetes diagnosis, and people who do are told to use a diabetes GLP-1 from the state’s preferred list instead.[2][3] For them the route is Ozempic, Trulicity or Victoza first. Mounjaro, the diabetes version of Zepbound, is non-preferred, and the list asks for trials of two preferred drugs for six months each before a non-preferred one.[4] ## What does Montana require for Zepbound and sleep apnea? More than most states. The adult needs a sleep study from the past 12 months showing an apnea-hypopnea index (AHI) of 15 or more, a BMI of at least 30 at the time of that study, and a diagnosis made by a sleep specialist or a clinic that reviews sleep studies.[3] Then comes the step that sets Montana apart: at least six months of continuous positive airway pressure (PAP) before the drug starts, and a promise to keep using it.[3] The form asks for two AHI results, one without CPAP and one with it, and adds a note that decides many cases. If the patient reaches an AHI under 15 on CPAP, Zepbound will not be approved.[3] In practice the route is for people whose apnea stays moderate or worse even on the machine, not for people who simply dislike wearing a mask. [Nevada Medicaid, by contrast, asks only for continued CPAP use](https://glpwatchdog.org/research/nevada-medicaid-glp1-coverage). The label itself sets no CPAP condition; it covers moderate to severe sleep apnea in adults with obesity.[8] Our guide to [the trials behind Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) explains how the drug was tested alongside CPAP. Renewals step up in stages. The first, after six months, needs at least 5% weight loss from baseline and continued PAP use, and it buys another six months.[3] The one-year renewal asks for a lower AHI, and later renewals, issued for 12 months, need the BMI held or reduced.[3] ## Does Montana Medicaid cover Wegovy for heart disease? Yes, with prior authorization. The adult must have a documented past heart attack or stroke, with the date, or peripheral artery disease backed by chart notes, and a BMI over 27.[2] That is close to the label, which covers adults with established heart disease and either obesity or overweight.[9] The form also wants a reduced-calorie diet and activity plan and a signed acknowledgment of the drug’s warnings.[2] The specialist rule is the part that trips up primary care. The drug must be prescribed by or with a cardiac specialist, and a prescriber outside a specialty clinic has to attach a copy of an annual consult with one.[2] Approval then runs a full 12 months, longer than in many states. Renewal needs signs that heart risk is improving, which the form lets the prescriber show through weight, waist size, blood pressure or cholesterol.[2] ## What about Wegovy for fatty liver disease (MASH)? Montana covers it for adults whose MASH has not reached cirrhosis and whose liver scarring sits at stage F2 or F3, the same range as the label.[2][9] The diagnosis has to rest on a liver biopsy or a specialized ultrasound such as FibroScan, and a gastroenterologist or liver specialist must prescribe it or be consulted each year.[2] Blood pressure, cholesterol and other related conditions must already be on the highest tolerated treatment.[2] Renewal is liver-based rather than weight-based. At the 12-month review, and at least every four years after, the file needs a repeat scan or biopsy showing the liver disease improved without the scarring getting worse, or the reverse.[2] The FDA approved this use on an accelerated basis, so it still depends on a confirmatory trial; our page on [GLP-1s for MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers what the evidence shows so far.[9] ## How does a prescriber file the request? Each drug has its own form, posted on Mountain Pacific’s pharmacy resources page. The prescriber completes the section for the right use, attaches the chart notes, study results and specialist consult, and faxes it to the state’s Drug Prior Authorization Unit at 1-800-294-1350.[2][3] Questions go to the unit at 1-800-395-7961.[5] Missing attachments are the most common fixable reason for a denial, so a complete packet on the first try saves weeks. ## How do you appeal a Montana Medicaid denial? First read the reason. A denial for a missing sleep study, consult or BMI can often be cured by resending the form with the record. A denial because the only diagnosis is obesity, or because CPAP alone brought the AHI under 15, follows the written rules and is hard to overturn.[1][3] For a formal fair hearing, Montana’s rule says the request must reach the department within 90 days of the date the notice was mailed.[6] Any clear written statement contesting the decision counts as a request, and it goes to the Office of Fair Hearings, P.O. Box 202953, Helena, MT 59620-2953.[6] Our guide to [building a prior authorization appeal](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what evidence to include, and the [Montana state page](https://glpwatchdog.org/states/montana) gathers the state’s coverage facts in one place. ## What are the options if Montana Medicaid says no? Paying cash is the usual one. Manufacturer copay cards are closed to Medicaid members; Lilly’s terms exclude anyone enrolled in a government-funded program, Medicaid included.[10] As of November 2026, Novo Nordisk’s self-pay price is $349 a month for most Wegovy pen doses and starts at $149 for the lowest Wegovy pill dose, and Lilly charges $299 for the starting Zepbound dose, $399 at 5 mg and $449 for higher doses refilled on schedule.[10][11] Check each program’s rules on government coverage before signing up. Our roundup of the [lowest-cost ways to buy a GLP-1 without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares the options. ## Frequently asked questions ### Does Montana Medicaid cover Wegovy for weight loss? No. Montana lists drugs used for weight loss among the drugs its Medicaid program does not cover. As of November 2026, a prior authorization can approve Wegovy for an adult without type 2 diabetes with a past heart attack or stroke, or with peripheral artery disease, whose BMI is over 27, or who has MASH with F2 to F3 liver scarring. ### Does Montana Medicaid cover Zepbound for sleep apnea? Yes, with prior authorization, but only after CPAP. The adult needs an AHI of 15 or more on a sleep study from the past year, a BMI of at least 30, a sleep specialist's diagnosis, no type 2 diabetes, and six months of continuous PAP use. If CPAP brings the AHI below 15, the request is denied. ### Does Montana Medicaid cover Ozempic? Yes, for type 2 diabetes. Ozempic injections, Trulicity and Victoza are preferred GLP-1s on Montana's September 2026 drug list. Mounjaro and Rybelsus are non-preferred and need trials of two preferred drugs for six months each. Ozempic is not covered for weight loss. ### Does Montana Medicaid require a specialist for Wegovy? Yes. For heart disease the drug must be prescribed by or with a cardiac specialist, and for MASH by or with a gastroenterologist or liver specialist. A prescriber outside a specialty clinic must attach a copy of an annual consult with the right specialist. ### What is the deadline to appeal a Montana Medicaid denial? Montana's hearing rule gives a Medicaid member 90 days from the date the notice was mailed for the request to reach the department. Any clear written statement contesting the decision counts, and it goes to the Office of Fair Hearings in Helena. ## References 1. Montana Department of Public Health and Human Services How Your Montana Healthcare Prescription Drug Program Benefit Works. dphhs.mt.gov. 2026. https://dphhs.mt.gov/MontanaHealthcarePrograms/Medicaid/pharmacy 2. Montana Healthcare Programs Prior Authorization Request Form for Use of Wegovy (semaglutide injection), August 2026. Mountain Pacific. 2026. https://mountainpacific.org/download/25789/ 3. Montana Healthcare Programs Prior Authorization Request Form for Use of Zepbound (tirzepatide), November 2025. Mountain Pacific. 2025. https://mountainpacific.org/download/26184/ 4. Montana Healthcare Programs Preferred Drug List (PDL), September 10, 2026. medicaidprovider.mt.gov. 2026. https://medicaidprovider.mt.gov/docs/pharmacy/2026/Sept2026508CompliantBlackPDL.pdf 5. Mountain Pacific Drug Prior Authorization. mountainpacific.org. 2026. https://mountainpacific.org/our-services/pharmacy-services/drug-prior-authorization/ 6. State of Montana Mont. Admin. R. 37.5.307: Opportunity for Hearing. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/montana/Mont-Admin-r-37.5.307 7. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 8. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 9. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 10. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 11. Novo Nordisk Wegovy savings offer and self-pay pricing. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html --- Cite as: GLP Watchdog, Nora Bissett, "Does Montana Medicaid Cover Wegovy or Zepbound? Heart, MASH and Sleep Apnea Rules", published 2026-11-07. https://glpwatchdog.org/research/montana-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/montana-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.